A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer . Adding the drug enzalutamide to standard hormone therapy reduced the risk of premature death by more than 40% in patients whose prostate cancer had returned, a large international clinical trial has found. The findings were simultaneously published in The New England Journal of Medicine and presented Sunday at a meeting of the European Society for Medical Oncology in Berlin. The